Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mineralys Therapeutics Inc

MLYS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$25.64

▼ -1.72%

Market Cap $2.27B · Vol 246.41K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.27B

Mid Cap

Div Yield

N/A

EPS Growth

-38.18%

YoY

RSI (14)

35.16

Momentum

Beta

0.66

vs Market

52W High

$47.65

46.19% below

52W Low

$14.16

81.07% above

Volume

246.41K

Avg 288.73K

P/B

4.58

Price-to-book

ROE

-36.91%

Return on equity

Free Float

94.52%

Public shares

Shariah Compliance8 STANDARDS

✗ Mineralys Therapeutics Inc (MLYS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MLYS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.25%

-6.01%

-5.98%

-7.10%

YTD

-29.35%

+81.46%

+105.61%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-154,651,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-36.91%
ROA · ROIC	-35.65% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.58
P/FCF	N/A
EPS Growth	-38.18%
Outstanding Shares	88.41M

Technical Indicators

50-Day SMA	$26.41
200-Day SMA	$30.75
RSI (14)	35.16
Beta	0.66
52-Week High	$47.65
52-Week Low	$14.16

Volume Today	246.41K
Avg Daily Volume (30D)	288.73K
Relative Volume	0.85x
Volatility (10D)	27.17
Volatility (30D)	34.51
Free Float	94.52%

Analyst Consensus

BUY

Current Price $25.64

Mean Target $48.50

52W Low$14.16 52W High$47.65

Current

Target

$14.16 $47.65

Current Analyst target

+89.16% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00ZXN1GR9

ISINUS6031701013

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.